Day One Biopharmaceutical... (DAWN)
Day One Biopharmaceuticals Statistics
Share Statistics
Day One Biopharmaceuticals has 101.36M shares outstanding. The number of shares has increased by 15.5% in one year.
| 101.36M |
| 15.5% |
| 0.01% |
| 97.02% |
| 74.66M |
| 10,394 |
| 0.77% |
Short Selling Information
The latest short interest is 12.61M, so 12.44% of the outstanding shares have been sold short.
| 12.61M |
| 12.44% |
| 18.51% |
| 10.03 |
Valuation Ratios
The PE ratio is -12.42 and the forward PE ratio is -7.7. Day One Biopharmaceuticals's PEG ratio is 0.22.
| -12.42 |
| -7.7 |
| 9.04 |
| 1 |
| 2.36 |
| -14.78 |
| 0.22 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Day One Biopharmaceuticals.
| n/a |
| n/a |
| n/a |
| n/a |
Financial Position
The company has a current ratio of 7.66, with a Debt / Equity ratio of 0.01.
| 7.66 |
| 7.61 |
| 0.01 |
| -0.01 |
| -0.03 |
| 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| n/a |
| n/a |
| n/a |
| $724,646.41 |
| $-527,602.21 |
| 181 |
| 0.23 |
| 1.59 |
Taxes
| -7.14M |
| 8.09% |
Stock Price Statistics
The stock price has increased by -51.99% in the last 52 weeks. The beta is -1.3, so Day One Biopharmaceuticals's price volatility has been lower than the market average.
| -1.3 |
| -51.99% |
| 6.8 |
| 10.8 |
| 44.87 |
| 1,346,608 |
Income Statement
In the last 12 months, Day One Biopharmaceuticals had revenue of 131.16M and earned -95.5M in profits. Earnings per share was -1.02.
| 131.16M |
| 125.88M |
| -217.27M |
| -95.5M |
| -217.27M |
| n/a |
| -1.02 |
Balance Sheet
The company has 124.97M in cash and 2.6M in debt, giving a net cash position of 122.37M.
| 124.97M |
| 2.6M |
| 122.37M |
| -554.08M |
| 534.36M |
| 460.77M |
Cash Flow
In the last 12 months, operating cash flow was -78.11M and capital expenditures -2.17M, giving a free cash flow of -80.28M.
| -78.11M |
| -2.17M |
| -80.28M |
| -0.86 |
Margins
Gross margin is 95.98%, with operating and profit margins of -165.65% and -72.81%.
| 95.98% |
| -165.65% |
| -67.36% |
| -72.81% |
| -165.65% |
| -165.65% |
| -61.21% |
Dividends & Yields
DAWN does not appear to pay any dividends at this time.
| n/a |
| n/a |
| n/a |
| n/a |
| n/a |
| n/a |
Analyst Forecast
The average price target for DAWN is $32, which is 390.8% higher than the current price. The consensus rating is "Buy".
| $32 |
| 390.8% |
| Buy |
| 7 |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| n/a |
| n/a |
| n/a |
| n/a |
Scores
| 5.61 |
| 2 |